NCT02140333

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: The First Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether 100mg erlotinib had similar effect compared with 150mg erlotinib in NSCLC patients with EGFR mutation in China.

Detailed description

In China it was confirmed that 150mg Erlotinib was effective in NSCLC patients wtih EGFR mutation, but reducing dose occurring in some patients because of the drug related side-effects. Thus, we sought to investigate that in Chinese patients with EGFR mutation whether low dose (100mg) Erlotinib had similar efficacy but lower toxcities compared with standad dose (150mg) Erlotinib.

Conditions

• NSCLC
• EGFR Mutation

Interventions

Type	Name	Description
DRUG	Erlotinib	100mg vs. 150mg

Timeline

• Start date: 2013-08-01
• Primary completion: 2018-08-01
• Completion: 2018-12-01
• First posted: 2014-05-16
• Last updated: 2015-02-12

Locations

1 site across 1 country: China